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ABSTRACT
Objective. Impaired hand function in 
systemic sclerosis (SSc) is a primary 
cause of disability and contributes di-
minished health-related quality of life. 
The objective of the present study was 
to evaluate sociodemographic, lifestyle, 
and disease-related factors indepen-
dently associated with hand function in 
SSc. 
Methods. Patients enrolled in the Scle-
roderma Patient-centered Interven-
tion Network Cohort who completed 
baseline study questionnaires between 
March 2014 and September 2017 were 
included. Hand function was measured 
using the Cochin Hand Function Scale 
(CHFS). Multiple linear regression 
analysis was used to identify independ-
ent correlates of impaired hand function.
Results. Among 1193 participants (88% 
female), the mean CHFS score was 13.3 
(SD=16.1). Female sex (standardised 
regression coefficient, beta (β)=.05), 
current smoking (β=.07), higher BMI 
(β=.06), diffuse SSc (β=0.14), more 
severe Raynaud’s scores (β=.23), more 
severe finger ulcer scores (β=.23), 
moderate (β=0.19) or severe small 
joint contractures (β=.20), rheumatoid 
arthritis (β=0.07), and idiopathic in-
flammatory myositis (β=0.06) were sig-
nificantly associated with higher CHFS 
scores (more impaired hand function). 
Consumption of 1–7 alcoholic drinks 
per week (β=-0.07) was associated with 
lower CHFS scores (less impaired hand 
function) compared to no drinking.
Conclusion. Multiple factors are asso-
ciated with hand function in SSc. The 
presence of moderate or severe small 
joint contractures, the presence of digi-
tal ulcers, and severity of Raynaud’s 
phenomenon had the largest associa-
tions. Effective interventions are need-
ed to improve the management of hand 
function in patients with SSc.
Introduction
Systemic sclerosis (SSc, or sclero-
derma) is a rare autoimmune disease 
characterised by vascular injury, im-
mune dysfunction and an abnormal 
fibrotic process that can affect multi-
ple organ systems including the skin, 
lungs, gastrointestinal tract and cardio-
vascular system (1, 2). SSc is notable 
for significant disruptions to activities 
of daily living, high levels of disability, 
and poor health-related quality of life 
(HRQL) (1-5) even compared to pa-
tients with other rheumatic diseases (4, 
5). Impaired hand functioning in SSc is 
a primary cause of disability and con-
tributes to lower HRQL, limitations in 
daily activities, and increased need for 
home care (6-8).
Across studies, patients with SSc con-
sistently rank concerns related to hand 
function at the top of their list of prob-
lems with the greatest impact on their 
daily lives (8, 9). Contractures and de-
formities of the hand, consisting of de-
creased flexion and limited extension 
as well as reduced thumb abduction, 
are present in approximately 90% of 
patients with SSc (8, 9). Other disease 
manifestations that may be linked to re-
duced hand function include Raynaud’s 
phenomenon, digital ulcers, skin thick-
ening, calcinosis, synovitis, and tendon 
friction rubs (6-14). However, only two 
studies (n=190 and n=213) have used 
multivariable analyses to examine fac-
tors associated with hand function in 
SSc (13, 14). Those studies reported 
that digital ulcers were significantly 
associated with reduced hand function, 
as measured by the Cochin Hand Func-
tion Scale (CHFS) (8, 15), but neither 
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study reported multivariable results 
for other factors that may contribute 
to poor hand function. There is a need 
to better understand factors contribut-
ing to functional impairments of the 
hands in SSc in order to identify po-
tential targets for education, prevention 
and treatment. Thus, the objective of 
the present study was to evaluate soci-
odemographic, lifestyle, and disease-
related factors that may influence hand 
functioning in SSc. 
Patients and methods
Patients and procedure
The study sample consisted of patients 
enrolled in the Scleroderma Patient-
centered Intervention Network (SPIN) 
Cohort who completed study question-
naires from March 2014 through Sep-
tember 2017 (16). Patients in the SPIN 
Cohort were enrolled at 37 centres in 
Canada, the USA, the UK, France, and 
Spain. To be eligible for the SPIN Co-
hort, patients must be classified by a 
SPIN physician as having SSc accord-
ing to the 2013 ACR/EULAR classifi-
cation criteria (17); be at least 18 years 
of age; have the ability to give informed 
consent; be fluent in English, French or 
Spanish; and have access and be able to 
respond to questionnaires via the inter-
net. The SPIN sample is a convenience 
sample. Eligible patients are invited by 
the attending physician or a supervised 
nurse coordinator to participate in the 
SPIN Cohort, and written informed con-
sent is obtained. The local SPIN physi-
cian or supervised nurse coordinator 
then completes a medical data form that 
is submitted online to initiate patient 
registration in the SPIN Cohort. After 
completion of online registration, an 
automated welcoming email is sent to 
participants with instructions on how to 
activate their SPIN online account and 
how to complete the SPIN Cohort pa-
tient measures online. Participants com-
plete outcome measures upon enrolment 
and subsequently every 3 months. Pa-
tients who completed all study variables 
at baseline were included in this study. 
The SPIN Cohort study was approved 
by the Research Ethics Committee of 
the Jewish General Hospital, Montreal, 
Canada and by the Institutional Reviews 
Boards of each participating centre.
Measures
- Sociodemographic and medical data 
Patients provided age, gender, marital 
status, years of education, number of 
cigarettes smoked per week, and num-
ber of alcoholic drinks per week. SPIN 
physicians completed a medical data 
form that included all items of the 2013 
ACR/EULAR SSc classification crite-
ria (17) and provided time since first 
non-Raynaud’s phenomenon symptoms 
and diagnosis, SSc subtype (limited or 
diffuse cutaneous SSc) (18), presence 
of overlap syndromes (systemic lupus 
erythematosus, rheumatoid arthritis, 
Sjögren’s syndrome, idiopathic inflam-
matory myositis), and presence of joint 
contractures (no/mild (0–25%) versus 
moderate/severe (>25%) limit in range 
of motion). 
Standard numeric rating scales were 
completed by patients for Raynaud’s 
severity in the past week and severity 
of finger ulcers, ranging from 0 (not se-
vere at all) to 10 (unbearable).
- Hand function
The 18-item Cochin Hand Function 
Scale (CHFS) was developed to meas-
ure hand function limitations among 
patients with rheumatoid arthritis. 
CHFS items assess ability to perform 
hand-related activities (e.g. kitchen, 
dressing oneself, hygiene, writing/typ-
ing). Items are scored on a 0-5 Likert 
scale (0=without difficulty; 5=impos-
sible). The total score is obtained by 
adding the scores of all items (range 
0-90), and higher scores indicate more 
difficulty in hand function. The CHFS 
has been validated in SSc (15).
Statistical analyses
Descriptive statistics for the sample 
were calculated as means and stand-
ard deviations (SDs) for continuous 
variables and counts and percentages 
for categorical variables. CHFS scores 
were compared across sociodemo-
graphic and clinical variables using 
univariate linear regression. Multiple 
linear regression was used to assess 
the independent associations of soci-
odemographic (sex, age, marital sta-
tus, education, smoking status, alcohol 
consumption and BMI) and medical 
variables with hand function, as meas-
ured with the CHFS. Medical vari-
ables to be included in the model were 
defined a priori by the research team 
and included disease duration, disease 
subtype, patient-reported severity of 
Raynaud’s and finger ulcers, presence 
of puffy fingers, presence of sclerodac-
tyly, presence of skin thickening proxi-
mal to the metacorpophalangeal joints, 
presence of tendon friction rubs, pres-
ence of small joint contractures, pres-
ence of systemic lupus erythematosus, 
Sjögren’s syndrome, and idiopathic in-
flammatory myositis. 
The assumption of normal distribution 
of residuals in the regression model 
was tested using a normal probabil-
ity plot. Additionally, correlations be-
tween independent variables and toler-
ances were calculated to check for mul-
ticollinearity. All statistical analyses 
were conducted using Stata (v. 13), and 




In total, 1193 participants had com-
plete data for all variables in the regres-
sion analyses and were included. There 
were 146 men (12%) and 1047 women 
(88%; Table I). Most patients were 
married or living as married (73%). 
Mean time since first non-Raynaud’s 
symptoms was 11.2 (SD=8.7) years; 
mean time since diagnosis was 9.4 
(SD=7.7) years. The mean CHFS score 
was 13.3 (SD=16.1).
Associations with hand function
Unadjusted associations of sociode-
mographic and disease variables with 
CHFS scores are shown in Table I. In 
bivariate analyses, higher age (stand-
ardised regression coefficient, beta 
(β)=-0.10), being married (β=-0.12), 
more years of education (β=-0.07), 
drinking 1–7 and drinking 8 or more 
glasses of alcohol per week (relative 
to no alcohol, β=-0.11 and β=-0.09, 
respectively) were significantly asso-
ciated with lower CHFS scores (less 
impaired hand function). Female sex 
(β=.07), current smoking (β=.10), 
diffuse disease (β=0.28), higher pa-
tient-reported severity of Raynaud’s 
(β=0.35) and finger ulcers (β=0.42), 
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presence of sclerodactyly (β=0.09), 
thickening of the skin of the fingers 
(β=0.21), current tendon friction rubs 
(relative to never; β=0.15), tendon fric-
tion rubs in the past (relative to never; 
=0.15), moderate (relative to no/mild; 
β=0.31) or severe (relative to no/mild); 
β=0.29) small joint contractures, pres-
ence of rheumatoid arthritis (β=0.10), 
and idiopathic inflammatory myositis 
(β=0.09) were significantly associated 
with higher CHFS scores (more im-
paired hand function). 
Results from the multivariable linear re-
gression are shown in Table II. The R2 
for the model was 0.375, and adjusted R2 
was 0.362. Female sex (β=0.05, p=.035), 
current smoking (β=0.07, p=0.004), 
higher BMI (β=0.06, p=0.012), diffuse 
SSc (β=0.14, p<0.001), more severe 
Raynaud’s scores (β=0.23, p<0.001), 
more severe finger ulcer scores (=0.23, 
p<.001), moderate (β=0.19, p<0.001) or 
severe small joint contractures (β=0.20, 
p<0.001), rheumatoid arthritis (β=0.07, 
p=0.004), and idiopathic inflammatory 
myositis (β=0.06, p=0.020) were sig-
nificantly associated with higher CHFS 
scores (more impaired hand function). 
Consumption of 1–7 alcoholic drinks 
per week (β=-0.07, p=0.004), on the 
other hand, was associated with lower 
CHFS scores (less impaired hand func-
tion) compared to no drinking.
Regression diagnostics found no evi-
dence for deviation from the assump-
tion of normal distribution of residuals 
based on a normal probability plot. All 
tolerance values were between 0.64 and 
0.96, indicating that multicollinearity 
was not an issue.
Discussion
The main finding of this study was that 
the presence of digital ulcers, the pres-
ence of moderate or severe contractures 
of the small joints, and patient-reported 
Raynaud’s phenomenon severity were 
the most robust independent correlates 
of impaired hand function in patients 
with SSc with diffuse disease subtype 
also strongly associated. Additionally, 
female sex, current smoking, higher 
BMI and comorbid rheumatoid arthri-
tis and idiopathic inflammatory myosi-
tis were significantly associated with 
more impaired hand function.
Raynaud’s phenomenon and digital ul-
cers are both common clinical features 
in patients with SSc, and in the SPIN 
Cohort, 99% of patients had Raynaud’s 
phenomenon and 34% had digital ul-
cers. A number of pharmacologic and 
non-pharmacological treatments are 
available to manage these symptoms. 
Different vasodilating drug therapies 
are available to reduce Raynaud’s and 
to prevent and improve healing of digi-
tal ulcers (19-23). In addition, treat-
ment of Raynaud’s phenomenon typi-
cally involves lifestyle modification to 
reduce exposure to potential triggers, 
including avoiding exposure to cold 
and maintaining whole body and digi-
tal warmth, smoking cessation, avoid-
ing medications that worsen vasocon-
striction and behavioural interventions 
to manage stress (21, 23, 24). On the 
other hand, current pharmacologic and 
non-pharmacological treatments fail 
to completely control Raynaud’s phe-
nomenon and prevent digital ulcers, 
and they are not tolerated by many 
SSc subjects. Our data underscore the 
important impact that Raynaud’s phe-
nomenon and digital ulcers have on 
patients and send a strong signal that 
novel, effective and well-tolerated in-
terventions are still required.
There are no well-proven treatments for 
hand contractures in SSc. Three RCTs 
have evaluated physical or occupa-
tional therapy interventions to improve 
hand function in SSc, but all were lim-
ited by small samples (n <20 per arm) 
and significant methodological short-
comings (25). An RCT (n=53) of a 12-
week multidisciplinary day treatment 
program, which included hand exercis-
es, reported grip strength and reduced 
disability compared to usual care 24 
weeks post-randomisation (26). More 
recently, another RCT tested a one-
month general SSc home-based exer-
cise therapy program, which included 
hand exercises (n=218) (27). The pro-
gram improved hand function signifi-
cantly at 6-months follow-up, but gains 
were no longer statistically significant 
at 12-months post-randomisation, pos-
sibly because the program did not fo-
cus specifically on hand function and 
that the one-month program did not 
provide resources to support ongoing 
patient adherence. One concern is that, 
while referral to hand therapists with 
experience in the treatment of SSc is 
often suggested to improve joint mo-
bility, access to these services is diffi-
cult for many patients (16). The SPIN-
HAND trial, which is currently under-
way, will evaluate the effectiveness of 
an online, self-guided program of hand 
exercises designed to improve hand 
function (28). Alternatively, given the 
important contribution of contractures 
to functional limitations, future efforts 
should also be directed to prevention of 
contractures since reversibility remains 
a significant challenge.
The present study has limitations that 
should be considered in interpreting re-
sults. First, the SPIN Cohort constitutes 
a convenience sample of SSc patients 
receiving treatment at a SPIN recruit-
ing centre, and patients at these centres 
may differ from those in other settings. 
Additionally, SSc patients in the SPIN 
Cohort complete questionnaires online, 
which may further limit the generalis-
ability of findings. A recent comparison 
between SPIN Cohort participants and 
the European Scleroderma Trials and 
Research (EUSTAR) and Canadian 
Scleroderma Research Group (CSRG) 
cohorts, however, showed that the SPIN 
Cohort is broadly comparable with 
these cohorts, increasing confidence 
that insights gained from the SPIN 
Cohort should be generalisable (29). 
An additional limitation of the present 
study relates to the nature of disease 
characteristics included in the analyses. 
Specifically, the majority of the vari-
ables included in the models consisted 
of fairly crude indicators of either the 
presence or absence of a particular dis-
ease factor, and most did not reflect 
severity, which may have reduced de-
tected associations. We have included 
patient-reported severity of finger ul-
cers, but not other factors such as pres-
ence of infection, depth or area of the 
ulcer. Furthermore, while other factors 
may have been of interest (e.g. socio-
economic status, access to healthcare), 
data for these factors were not available 
or variables were not selected to be in-
cluded in our a priori model, thus were 
beyond the scope of the present paper. 
No information was available on treat-
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ments administered to patients in the 
SPIN Cohort. Finally, although the 
medical variables included in the model 
were defined a priori by the research 
team with expertise in hand function 
problems in SSc, due to the scarcity of 
previous studies in this area, our study 
was exploratory in nature. 
In sum, the present study is the first 
to examine the independent associa-
tions of sociodemographic, lifestyle, 
and disease-related factors with hand 
functioning in a large cohort of SSc 
patients. Results highlight that multi-
ple factors may contribute to hand dis-
ability in SSc, with joint contractures, 
patient-reported severity of Raynaud’s 
phenomenon and digital ulcers having 
the largest associations. Adequately-
tested prevention strategies, medical 
treatments, and rehabilitation programs 
are needed to improve the management 
of hand function problems in patients 
with SSc.
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Variable N (%) or  Unstandardised regression Standardised p-value
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    (95% Confidence Interval) coefficient
Demographic
Female sex, n (%) 1047 (88) 3.21 (5.99, 0.43) 0.07 0.024
Age in years, mean (SD) 55.1 (12.3) -0.14 (-0.21, -0.06) -0.10 <0.001
Married or living as married, n (%) 865 (73) -4.19 (-6.23, -2.16) -0.12 <0.001
Education in years, mean (SD) 15.1 (3.5) -0.30 (-0.56, -0.05) -0.07 0.021
Current Smoker, n (%) 88 (7) 5.86 (2.37, 9.33) 0.10 0.001
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1-7 439 (37) -3.71 (-5.63, -1.78) -0.11 <0.001
8+ 89 (7) -5.52 (-9.05, -1.98) -0.09 <0.001
BMI, mean (SD) 25.6 (5.8) -0.00 (-0.16, 0.16) -0.00 0.978
Disease characteristics
Time since onset first non-Raynaud’s symptom in years, mean (SD) 11.2 (8.7) 0.03 (-0.08, 0.13) 0.01 0.630
Diffuse SSc, n (%) 475 (40) 9.12 (7.32, 10.91) 0.28 <0.001
Presence of Raynaud’s, n (%)a 1171 (99) 1.64 (-6.31, 9.59) 0.01 0.686
Patient-reported severity of Raynaud’s, mean (SD) 3.7 (2.8) 1.99 (1.69, 2.30) 0.35 <0.001
Presence of finger ulcers, n (%) 400 (34) 6.23 (4.32, 8.13) 0.18 <0.001
Patient-reported severity of finger ulcers, mean (SD) 1.6 (2.7) 2.54 (2.23, 2.85) 0.42 <0.001
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Cochin Hand Function Scale total score, mean (SD) 13.3 (16.1) -- -- --
aDue to missing values: n=1187.
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Variable Unstandardised Standardised p
 regression coefficient regression 




Female sex 2.46 (4.74, 0.17) 0.05 0.035
Age (years) 0.00 (-0.06, 0.06) 0.03 0.990
Married or living as married -1.44 (-3.13, 0.25) -0.04 0.094
Education (years) -0.11 (-0.32, 0.11) -0.02 0.321
Current smoker 4.16 (1.30, 7.02) 0.07 0.004
Alcohol consumption (drinks/week)
0 reference -- --
1-7 -2.28 (-3.85, -0.71) -0.07 0.004
8+ -2.46 (-5.37, 0.44) -0.04 0.097
BMI 0.16 (0.04, 0.29) 0.06 0.012
Disease characteristics
Time since onset first non-Raynaud’s symptom (years) 0.09 (-0.00, 0.18) 0.05 0.054
Diffuse SSc 4.54 (2.70, 6.39) 0.14 <0.001
Patient-reported severity of Raynaud’s (0-10) 1.32 (1.04, 1.61) 0.23 <0.001
Patient-reported severity of finger ulcers (0-10) 1.41 (1.10, 1.72) 0.23 <0.001
Presence of puffy fingers 1.11 (-0.44, 2.66) 0.03 0.160
Presence of sclerodactyly 1.09 (-0.97, 3.16) 0.03 0.299
Presence of skin thickening of the fingers proximal to 0.21 (-1.61, 2.02) 0.01 0.823 
      the metacorpophalangeal joints 
Tendon friction rubs
Never reference -- --
Currently, with or without past 1.05 (-1.33, 3.42) 0.02 0.387
In the past, but not currently  2.06 (-0.40, 4.52) 0.04 0.101
Small joint contractures
No/Mild reference -- --
Moderate 8.20 (6.11, 10.30) 0.19 <0.001
Severe 13.04 (9.90, 16.18) 0.20 <0.001
Presence of systemic lupus erythematosus -1.83 (-6.40, 2.73) -0.02 0.431
Presence of Sjögren’s syndrome -0.36 (-2.95, 2.22) -0.01 0.782
Presence of rheumatoid arthritis 4.89 (1.60, 8.19) 0.07 0.004
Presence of idiopathic inflammatory myositis 3.84 (0.60, 7.09) 0.06 0.020
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